Search
forLearn
5 / 801 resultsResearch
5 / 689 results
research Pregnancy in a Secondary Infertile Woman with Polycystic Ovarian Syndrome (PCOS) –A Case Report
A woman with PCOS successfully overcame secondary infertility and became pregnant with triplets after treatment.
research H13 Leprosy and psoriasis: a heated controversy
Leprosy and psoriasis were historically confused, but were finally distinguished as separate diseases in the 1800s.
research 070 Bacillary Load and Reactional States in Leprosy - A Surge in Severity the COVID Era?
The COVID-19 pandemic has led to more severe cases of Leprosy due to delayed medical care.
research Lepromatous Leprosy in a Renal Transplant Recipient
A kidney transplant patient developed leprosy, likely due to immunosuppression and genetic factors, and improved with treatment.
research Leprosy on the scalp
A man from Brazil had a rare case of leprosy on his scalp, which improved with treatment.
Community Join
5 / 1000+ resultscommunity Clascoterone - clearnet vendor
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
community Beeezula off label (winlevi compounded)
User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.
community Using WinLevi (Clascoterone) for Seborrheic Dermatitis and Acne
Winlevi (clascoterone) is discussed as a treatment for hormonal acne and seborrheic dermatitis due to its ability to block DHT and regulate sebum production. The post suggests that Winlevi could offer a novel approach for managing seborrheic dermatitis.
community Winlevi (clascoterone 1%) anyone trying it
Winlevi (clascoterone 1%) is being discussed as a potential hair loss treatment. Users are considering its use despite concerns about its delivery method.
community EMA is re-examining Winlevi (clascoterone at lower concentration)
Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.